Jubilant Pharmova Limited has informed the Exchange about General Updates- Completion of Sale and Transfer of API Business
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova has completed the sale and transfer of its API (Active Pharmaceutical Ingredients) business, as communicated to the stock exchange. The company has now fully divested this segment, which was a significant part of its pharmaceutical operations. No details on the buyer, deal value, or financial impact have been mentioned in this filing. This marks the conclusion of a previously announced strategic move to exit the API segment.
Shareholders should expect the company's revenue base to shrink as the API segment is no longer part of the business. The stock may react based on the sale proceeds received and the company's future focus on remaining businesses like radiopharma, contract manufacturing, and drug discovery.